Djurkovic‐Lazic 2009.

Trial name or title	School children with ADHD ‐ effects of once‐daily OROS methylphenidate treatment ADHD symptoms included improvement academic functioning
Methods	An ongoing cohort study of children and adolescents aged 7 to 14 years with ADHD treated with OROS‐methylphenidate
Participants	Number of participants screened: not stated Number of participants included: 32 Number of participants followed up: not stated Number of withdrawals: not stated Diagnosis of ADHD: DSM‐IV (subtype not stated) Age: range 7‐14 years' old IQ: not stated Sex: not stated Methylphenidate‐naïve: not stated Ethnicity: not stated Country: Serbia Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria Children with ADHD symptoms, team‐diagnosed by a psychiatrist, psychologist and neurologist
Interventions	Methylphenidate type: OROS Methylphenidate dosage: 18‐54 mg Administration schedule: once daily Duration of intervention: not stated Treatment compliance: not stated
Outcomes	Adverse events, vital signs, EEG (no further data)
Starting date	—
Contact information	J Djurkovic‐Lazic, Institute for Psychophisiological and Speach Pathology, Belgrade
Notes	Sample calculation: not stated Ethics approval: not stated Funding/vested interests: not stated Authors' affiliations: not stated Key conclusions of the study authors: (PRELIMINARY) "Besides our expecting on reduction of ADHD symptoms with minimal effects on vital sings, values on growth, tick, laboratory test, it considers too, better academic functioning social relationship with continual therapy" Comments from the review authors: we have not been able to obtain the full‐text report. Therefore, the data are incomplete.